SML3559
LAU-0901
≥98% (HPLC)
别名:
1,4-dihydro-2,4,6-trimethyl-3,5-Pyridinedicarboxylic acid 3-[2-(3,4-dichlorophenoxy)ethyl] 5-[2-(4-morpholinyl)-1-(4-morpholinylmethyl)ethyl] ester
InChI
1S/C29H39Cl2N3O7/c1-19-26(28(35)40-15-14-39-22-4-5-24(30)25(31)16-22)20(2)32-21(3)27(19)29(36)41-23(17-33-6-10-37-11-7-33)18-34-8-12-38-13-9-34/h4-5,16,19,23,32H,6-15,17-18H2,1-3H3
InChI key
WZWJKBCMEZITJW-UHFFFAOYSA-N
SMILES string
CC1C(C(OCCOC2=CC(Cl)=C(C=C2)Cl)=O)=C(NC(C)=C1C(OC(CN3CCOCC3)CN4CCOCC4)=O)C
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Highly potent and selective platelet-activating factor (PAF) receptor antagonist
LAU-0901 is a highly potent and selective platelet-activating factor (PAF) receptor antagonist that is neuroprotective in experimental stroke, and protective in a variety of inflammation models. LAU-0901 blocks pro-inflammatory signaling. LAU-0901 demonstrated efficacy in a mouse model of glioblastoma multiforme (GBM) alone and in combination with Avastin.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth
Frontiers in Pharmacology, 12 (2021)
Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke
Translational Stroke Research, 3, 154-163 (2012)
Blocking pro-inflammatory platelet-activating factor receptors and activating cell survival pathways: A novel therapeutic strategy in experimental ischemic stroke
Brain circulation, 6, 260-268 (2020)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持